PDF(Pubmed)
Abstract：
Background and objective Prolactin (PRL) has a high specificity toward breast cancer (BC), making it a valuable marker in both diagnosis and prognosis. In this study, we aimed to compare serum PRL levels between pre- and post-menopausal women with BC, as well as normal reference values. We also investigated the association of various risk factors with PRL levels in women with BC. Methods The study involved adult women diagnosed with BC based on clinical features and tissue histopathology receiving treatment at a tertiary care center in Pune, India. General and demographic information, anthropometric measurements (height, weight, and BMI), menstrual status (age at menarche and menopausal state), clinical presentation (signs and symptoms), duration of symptoms, and parity were recorded by using a pre-tested proforma based on hospital records or in-person interviews. Serum PRL was measured by the RIA method (sandwich assay). Results A total of 67 women (average age: 47.5 ± 11.8 years; 33 of them post-menopausal) with BC were included in the study. The participants had an average BMI of 24.9 ± 3.5 kg/m2, and 26 (39%) of them were overweight. The majority of women had BC stage IIA disease, involvement of the right side or upper outer quadrant, and had attained menarche after 14 years of age; 47 women had a BC duration of >3 months. Seven women were nulliparous, and the remaining had given birth to their first child before the age of 26 years. The average serum PRL level among the participants was 9.27 ± 7.62 ng/mL, with higher levels found in post-menopausal women compared to pre-menopausal women (11.08 vs. 7.51 ng/mL, respectively; p=0.08). Women with a higher stage and greater duration of disease had significantly higher serum PRL levels (p<0.001 for both). When compared with reference values, pre-menopausal women showed significantly lower (6.25 vs. 10.9, respectively; p=0.001) and post-menopausal women showed significantly higher (8.55 vs. 5.95; p=0.004) serum PRL levels. A positive correlation was found between serum PRL and age at the time of birth of the first child (p=0.068). Conclusions Based on our findings, PRL is an important hormone in the development of BC in women. Therapeutic modulation of PRL may be a realistic and novel approach to curing human BC, either administered alone or in combination with conventional treatments.
摘要：
背景与目的催乳素(PRL)对乳腺癌(BC)具有较高的特异性,使其成为诊断和预后的有价值的标志物。在这项研究中,我们旨在比较绝经前和绝经后女性BC患者的血清PRL水平，以及正常参考值。我们还调查了各种危险因素与女性BC患者PRL水平的关系。方法该研究涉及根据临床特征和组织病理学诊断为BC的成年女性，在浦那的三级护理中心接受治疗。印度。一般和人口统计信息，人体测量(身高，体重,和BMI），月经状态（初潮年龄和绝经状态），临床表现（体征和症状），症状持续时间，通过使用基于医院记录或面对面访谈的预先测试的形式记录和均等。通过RIA方法(夹心测定)测量血清PRL。结果共纳入67名女性（平均年龄：47.5±11.8岁；其中33名绝经后）的BC患者。参与者的平均BMI为24.9±3.5kg/m2，其中26人（39％）超重。大多数女性患有BC期IIA病，受累于右侧或上外侧象限，并在14岁后达到月经初潮；47名妇女的BC持续时间>3个月。七个女人是未产的，其余的人在26岁之前生下了第一个孩子。参与者的平均血清PRL水平为9.27±7.62ng/mL，与绝经前女性相比，绝经后女性的水平更高(11.08vs.7.51ng/mL，分别为；p=0.08)。具有较高分期和较长病程的女性具有显著较高的血清PRL水平(两者均p<0.001)。当与参考值比较时，绝经前妇女显着降低（6.25vs.分别为10.9；p=0.001）和绝经后妇女显着升高（8.55vs.5.95；p=0.004）血清PRL水平。在第一个孩子出生时，血清PRL与年龄之间存在正相关（p=0.068）。结论根据我们的发现，PRL是女性BC发展的重要激素。PRL的治疗调节可能是治愈人类BC的一种现实而新颖的方法，单独给药或与常规治疗联合给药。
